VNDA VANDA PHARMACEUTICALS INC
Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about VANDA PHARMACEUTICALS INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
8 rated views · 9 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 8 reports on VNDA from 6 analyst firms in the last 90 days (9 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it, 2 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Jefferies lowered its target from $5.75 (set 1 Jul 2026) to $4.50 on 27 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| B Riley Securities | Madison El-Saadi | Buy | 28 Oct 2026 | 12.00 USD |
| Cantor Fitzgerald | Olivia Brayer | Buy | 15 Feb 2026 | 11.00 USD |
| H.C. Wainwright | Raghuram Selvaraju | Buy | 5 Oct 2026 | 20.00 USD |
| Jefferies | Andrew Tsai | Hold | 27 Oct 2026 | 4.50 USD |
| Jefferies | Chris Howerton | Hold | 31 Dec 2025 | 7.50 USD |
| Oppenheimer | Les Sulewski | Buy | 23 Sep 2026 | 10.00 USD |
| UBS | Unnamed analyst | Buy | 5 Jan 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Sell | 6 Oct 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:35 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.